Julie Jacobs

2.2k total citations · 1 hit paper
33 papers, 1.4k citations indexed

About

Julie Jacobs is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Julie Jacobs has authored 33 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 12 papers in Immunology and 10 papers in Molecular Biology. Recurrent topics in Julie Jacobs's work include Cancer Immunotherapy and Biomarkers (14 papers), Cancer-related Molecular Pathways (7 papers) and Immune Cell Function and Interaction (6 papers). Julie Jacobs is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Cancer-related Molecular Pathways (7 papers) and Immune Cell Function and Interaction (6 papers). Julie Jacobs collaborates with scholars based in Belgium, United States and Switzerland. Julie Jacobs's co-authors include Patrick Pauwels, Filip Lardon, Evelien Smits, Christophe Deben, Vanessa Deschoolmeester, Jorrit De Waele, An Wouters, Karen Zwaenepoel, Marc Peeters and Christian Rolfo and has published in prestigious journals such as Cancer Research, International Journal of Molecular Sciences and British Journal of Cancer.

In The Last Decade

Julie Jacobs

32 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The potential and controversy of targeting STAT family members in cancer

2019 273 citations Yannick Verhoeven, Sam Tilborghs et al. Seminars in Cancer Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie Jacobs Belgium	19	760	513	376	307	267	33	1.4k
Wiam Bshara United States	25	746 1.0×	811 1.6×	314 0.8×	402 1.3×	328 1.2×	73	1.7k
Simona Ruggieri Italy	20	442 0.6×	782 1.5×	310 0.8×	317 1.0×	170 0.6×	51	1.5k
Rakesh R. Ramjiawan United States	6	688 0.9×	434 0.8×	449 1.2×	282 0.9×	222 0.8×	7	1.3k
Miriam Redrado Spain	20	518 0.7×	544 1.1×	233 0.6×	270 0.9×	177 0.7×	39	1.1k
Pedro P. López‐Casas Spain	25	978 1.3×	702 1.4×	317 0.8×	540 1.8×	340 1.3×	52	1.8k
Hao‐Xiang Wu China	22	596 0.8×	520 1.0×	251 0.7×	393 1.3×	289 1.1×	38	1.3k
Pablo Matar Argentina	19	673 0.9×	469 0.9×	413 1.1×	177 0.6×	308 1.2×	37	1.3k
Alberto Fusi Germany	21	909 1.2×	599 1.2×	362 1.0×	491 1.6×	251 0.9×	53	1.5k
Ying Ma China	20	620 0.8×	741 1.4×	480 1.3×	310 1.0×	243 0.9×	81	1.7k
Si-Qi Qiu China	14	420 0.6×	303 0.6×	281 0.7×	313 1.0×	161 0.6×	35	966

Countries citing papers authored by Julie Jacobs

Since Specialization

Citations

This map shows the geographic impact of Julie Jacobs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Jacobs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Jacobs more than expected).

Fields of papers citing papers by Julie Jacobs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Jacobs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Jacobs. The network helps show where Julie Jacobs may publish in the future.

Co-authorship network of co-authors of Julie Jacobs

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Jacobs. A scholar is included among the top collaborators of Julie Jacobs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Jacobs. Julie Jacobs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Flieswasser, Tal, Christel Vangestel, Alan Miranda, et al.. (2023). Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models. EJNMMI Radiopharmacy and Chemistry. 8(1). 8–8. 17 indexed citations

Brooks, Johnell O., et al.. (2023). What Makes Passengers Uncomfortable In Vehicles Today? An Exploratory Study of Current Factors that May Influence Acceptance of Future Autonomous Vehicles. SAE technical papers on CD-ROM/SAE technical paper series. 1. 9 indexed citations

Flieswasser, Tal, Laurie Freire Boullosa, Christophe Hermans, et al.. (2023). Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer. OncoImmunology. 12(1). 2192100–2192100. 6 indexed citations

Siozopoulou, Vasiliki, Christophe Hermans, Hilde Lambrechts, et al.. (2022). The prognostic impact of the immune signature in head and neck squamous cell carcinoma. Frontiers in Immunology. 13. 1001161–1001161. 13 indexed citations

Flieswasser, Tal, Jonas R.M. Van Audenaerde, Jorrit De Waele, et al.. (2022). The CD70-CD27 axis in oncology: the new kids on the block. Journal of Experimental & Clinical Cancer Research. 41(1). 12–12. 109 indexed citations

Jacobs, Julie, Christophe Deben, Christophe Hermans, et al.. (2020). Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients. Cancers. 12(4). 863–863. 19 indexed citations

Pauw, Ines De, Jorrit De Waele, Marc Peeters, et al.. (2020). Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status. British Journal of Cancer. 123(5). 752–761. 29 indexed citations

Sorber, Laure, Karen Zwaenepoel, Julie Jacobs, et al.. (2019). Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol. Cancers. 11(4). 458–458. 74 indexed citations

Bossche, Jolien Van den, Andreas Domen, Marc Peeters, et al.. (2019). Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. Cancers. 11(12). 1893–1893. 9 indexed citations

10.

Sorber, Laure, Karen Zwaenepoel, Julie Jacobs, et al.. (2019). Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions. Molecular Diagnosis & Therapy. 24(1). 113–124. 35 indexed citations

11.

Siozopoulou, Vasiliki, Elly Marcq, Julie Jacobs, et al.. (2019). Desmoid tumors display a strong immune infiltration at the tumor margins and no PD-L1-driven immune suppression. Cancer Immunology Immunotherapy. 68(10). 1573–1583. 14 indexed citations

12.

Verhoeven, Yannick, Sam Tilborghs, Julie Jacobs, et al.. (2019). The potential and controversy of targeting STAT family members in cancer. Seminars in Cancer Biology. 60. 41–56. 273 indexed citations breakdown →

13.

Bossche, Jolien Van den, Christophe Deben, Ines De Pauw, et al.. (2019). In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53. Molecular Oncology. 13(5). 1196–1213. 15 indexed citations

14.

Marcq, Elly, Jonas R.M. Van Audenaerde, Jorrit De Waele, et al.. (2019). Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression. International Journal of Molecular Sciences. 20(17). 4182–4182. 10 indexed citations

15.

Jacobs, Julie, Vanessa Deschoolmeester, Karen Zwaenepoel, et al.. (2018). Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. OncoImmunology. 7(7). e1440167–e1440167. 45 indexed citations

16.

Deben, Christophe, Vanessa Deschoolmeester, Jorrit De Waele, et al.. (2018). Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. Cancers. 10(4). 126–126. 46 indexed citations

17.

Bossche, Jolien Van den, Christophe Deben, Ken Op de Beeck, et al.. (2017). Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia. Journal of Cancer. 8(8). 1441–1452. 12 indexed citations

18.

Deben, Christophe, Ken Op de Beeck, Jolien Van den Bossche, et al.. (2017). MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients. Journal of Cancer. 8(12). 2154–2162. 4 indexed citations

19.

Deben, Christophe, Filip Lardon, An Wouters, et al.. (2016). APR-246 (PRIMA-1 MET ) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. Cancer Letters. 375(2). 313–322. 54 indexed citations

20.

Jacobs, Julie, Vanessa Deschoolmeester, Karen Zwaenepoel, et al.. (2015). CD70: An emerging target in cancer immunotherapy. Pharmacology & Therapeutics. 155. 1–10. 142 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact